The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
Saved in:
| Main Author: | J. Karalliedde |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
by: Emily Brown, et al.
Published: (2021-01-01) -
ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
by: F. I. Belyalov
Published: (2017-07-01) -
Significance and research advances of biomarker detection in end-stage renal disease complicated with infection
by: Chen Ting, et al.
Published: (2022-03-01) -
Effect of Pulmonary Hypertension Severity on Graft Function and Quality of Life after Transplantation in Patients with End-Stage Renal Disease
by: susan Mohammadi-Kebar, et al.
Published: (2022-01-01) -
Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
by: Sangmo Hong, et al.
Published: (2025-07-01)